Latest News — Page 5

How can blended capital unlock breakthroughs in pediatric cancer treatments?

Developing drugs for childhood cancers faces unique challenges—small patient populations, high risks, and limited commercial returns often deter traditional investors. This article examines why combining public grants, venture funding, and philanthropic support is critical to advancing therapies in oncology.

Read the full analysis to explore innovative financing models driving progress.
#SyenzaNews #oncology #biotechnology #innovation #HealthEconomics

📉 Are prescription drug prices finally easing?

A new analysis reveals a 3.1% decline, with potential ripple effects on market access, reimbursement strategies, and overall pharmaceutical economics.

Read the full breakdown to see what it means for stakeholders.

#SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #costeffectiveness

The European Medicines Agency’s Management Board met in Amsterdam on 10 and 11 June 2026. The European Commission reported that the first EU joint clinical assessment report appeared on 9 June 2026. Since the Health Technology Assessment Regulation took effect in January 2025, 18 JCAs have started. Seven Joint Scientific Consultations have finished under the Regulation, and the first JCAs for medical devices and in vitro diagnostics will begin in June 2026. Initiative Status Timing First EU joint clinical assessment […]

📱 Are older adults being left behind in the digital health revolution?

As populations age, digital exclusion is widening health gaps, limiting access to care, information, and services for seniors who lack the skills or tools to navigate online platforms. This growing divide demands urgent attention from policymakers and innovators alike.

Read the full analysis to explore solutions for a more inclusive future.
#SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #innovation

EMA and HMA have opened a public consultation on the draft EMRN Data Standards Framework, which sets out how the EU will govern data standards for medicines regulation. Comments close 18 September 2026.

🧬 Could your gut microbiota reveal clues about psychopathic traits?

New research highlights how distinct microbial profiles may serve as biomarkers, opening fresh paths for mental health diagnostics and targeted interventions in psychiatry.

Explore the study’s implications for precision approaches to behavioral health.

#SyenzaNews #biotechnology #precisionmedicine #innovation

South Africa’s drugmakers and the health department are at odds over lowest-price tenders. Pharmisa says cheaper imports have cost more than 2,500 jobs and eroded local manufacturing capacity.

The NICE Decision Support Unit and EEPRU have released updated Stata, Excel and R commands for mapping EQ-5D-3L data to the new EQ-5D-5L value set, giving UK HTA analysts a validated route to convert legacy three-level utility data ahead of NICE’s adoption of the five-level value set.

Why has Portugal’s Ordem dos Médicos welcomed the SINACC postponement?

The medical association says the surgery access system was still in testing and lacked safeguards, warning that reclassifying minor surgery could hide patients from waiting lists.

Read what 278,394 patients on the list means for the rollout.

#SyenzaNews #HealthEconomics #digitalhealth #healthcarepolicy

How are cell therapies redefining cancer care through rigorous HTA evaluation?

INCA’s latest analysis highlights how CAR-T and other advanced cell therapies are shifting oncology paradigms—balancing innovation with evidence-based access and cost-effectiveness.

Explore the full breakdown and its implications for global cancer treatment.
#SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

💊 Is it safe to stop statins in elderly patients for primary prevention?

A recent trial shows that deprescribing statins in older adults without established cardiovascular disease does not increase the risk of adverse outcomes, supporting more individualized prescribing decisions.

Discover the full trial results and implications for clinical practice.

#SyenzaNews #clinicaltrials #pharmaceuticals #costeffectiveness #healthcarepolicy

Is the US childhood vaccine schedule really out of step with peer nations?

A new analysis finds it aligns closely with other developed countries in both the number and timing of recommended vaccines.

Explore the full comparison and what it means for vaccine policy.
#SyenzaNews #globalhealth #HealthcareInnovation #healthcarepolicy #innovation

How can real-world data networks improve safety evaluations for multiple sclerosis therapies?

A new collaborative MS data initiative is enabling more robust assessments of treatment safety by pooling patient insights across sources.

Discover how this approach is advancing evidence generation in neurology.
#SyenzaNews #digitalhealth #clinicaltrials #datascience #innovation

💰 Is pembrolizumab delivering high value for HNSCC in Switzerland?

A new analysis confirms the immunotherapy offers strong cost-effectiveness, supporting smarter resource allocation and improved patient outcomes in oncology.

Explore the full economic evaluation and its implications for market access.

#SyenzaNews #oncology #HealthEconomics #costeffectiveness #MarketAccess

Is tirzepatide delivering better value than semaglutide for patients and payers?

A fresh analysis shows how tirzepatide can drive greater cost savings alongside improved health outcomes in obesity and type 2 diabetes management.

Discover the key findings shaping treatment and reimbursement decisions.

#SyenzaNews #pharmaceuticals #HealthEconomics #costeffectiveness

🚀 What if the first oral GLP-1 therapy just cleared its biggest regulatory hurdle in Europe?

The MHRA has approved orforglipron, delivering the continent’s first oral win and offering patients a convenient, needle-free option for weight management and type 2 diabetes.

Read the full story on this landmark approval.
#SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess